Aripiprazole

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Overweight

Conditions

Overweight, Hyperlipidemia, Cardiovascular Diseases

Trial Timeline

Oct 1, 2004 → Dec 1, 2005

NCT ID

NCT00222833

About Aripiprazole

Aripiprazole is a approved stage product being developed by Bristol Myers Squibb for Overweight. The current trial status is completed. This product is registered under clinical trial identifier NCT00222833. Target conditions include Overweight, Hyperlipidemia, Cardiovascular Diseases.

What happened to similar drugs?

0 of 20 similar drugs in Overweight were approved

Approved (0) Terminated (0) Active (20)

🔄Eloralintide + PlaceboEli LillyPhase 3

🔄Tirzepatide + PlaceboEli LillyPhase 3

🔄Maridebart cafraglutide + PlaceboAmgenPhase 3

🔄Semaglutide + Semaglutide PlaceboNovo NordiskPhase 3

🔄Semaglutide + PlaceboNovo NordiskPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01386086	Phase 3	Completed	Jun 1, 2011	Nov 1, 2013	Postpartum Depression
NCT00665444	Pre-clinical	Terminated	Apr 1, 2008	Aug 1, 2009	Bipolar Disorder
NCT00308074	Phase 2	Completed	Feb 1, 2006	Feb 1, 2009	Autism
NCT00619190	Phase 2	Completed	Jan 1, 2006	Jun 1, 2012	Autistic Disorder
NCT00608543	Approved	Completed	Oct 1, 2005	Jan 1, 2009	Major Depressive Disorder
NCT00312598	Pre-clinical	Completed	Aug 1, 2005	Apr 1, 2010	Schizophrenia
NCT00221416	Phase 3	Completed	Jun 1, 2005	Dec 1, 2008	Bipolar Disorder
NCT00221962	Approved	Completed	Apr 1, 2005	Apr 1, 2007	Attention Deficit Hyperactivity Disorder
NCT00209027	Pre-clinical	Terminated	Apr 1, 2005	Apr 1, 2011	Schizophrenia
NCT00438386	Approved	Completed	Apr 1, 2005	Jun 1, 2007	Generalized Anxiety Disorder
NCT00374348	Pre-clinical	Completed	Mar 1, 2005	May 1, 2008	Schizophrenia OCD
NCT00208169	Approved	Completed	Mar 1, 2005	Jun 1, 2007	Schizophrenia
NCT00220636	Approved	Completed	Mar 1, 2005	Jan 1, 2008	Depressive Disorder, Major
NCT00198055	Phase 2	Completed	Jan 1, 2005	Sep 1, 2007	Asperger's Disorder
NCT00250705	Approved	Completed	Nov 17, 2004	Mar 23, 2009	Conduct Disorder
NCT00222833	Approved	Completed	Oct 1, 2004	Dec 1, 2005	Overweight
NCT00223496	Approved	Completed	Sep 1, 2004	Sep 1, 2009	Bipolar Disorder
NCT00226317	Pre-clinical	Completed	Apr 1, 2004	Feb 1, 2008	Bipolar Disorder
NCT00194038	Approved	Completed	Apr 1, 2004	Jun 1, 2006	Bipolar Disorder
NCT00224822	Approved	Completed	Mar 1, 2004	Mar 1, 2007	Schizophrenia

Competing Products

20 competing products in Overweight

See all competitors

Product	Company	Stage	Hype Score
TERN-601	Terns Pharmaceuticals	Phase 2	32
LY3457263 + Tirzepatide + Placebo	Eli Lilly	Phase 1	29
LY3305677 + Placebo	Eli Lilly	Phase 1	29
LY3537031 + Placebo	Eli Lilly	Phase 1	33
Tirzepatide + Lisdexamfetamine Dimesylate + Placebo (oral) + Placebo (injection)	Eli Lilly	Phase 2	42
Eloralintide + Placebo	Eli Lilly	Phase 3	47
LY4064912 + LY4064912 + Placebo + Placebo	Eli Lilly	Phase 1	36
LY3437943 + Ethinyl Estradiol + Drospirenone	Eli Lilly	Phase 1	29
Tirzepatide + Acetaminophen	Eli Lilly	Phase 1	29
Tirzepatide + Placebo	Eli Lilly	Phase 2	39
Eloralintide + Placebo	Eli Lilly	Phase 3	47
LY3437943 + Placebo	Eli Lilly	Phase 1	29
LY3502970 + Placebo	Eli Lilly	Phase 1	29
Tirzepatide + Placebo	Eli Lilly	Phase 3	44
Eloralintide and Tirzepatide + Eloralintide	Eli Lilly	Phase 1	29
Tirzepatide + Placebo	Eli Lilly	Phase 3	40
LY3541105 + Placebo	Eli Lilly	Phase 1	29
Retatrutide + Placebo	Eli Lilly	Phase 2	35
LY4167586 + Placebo + LY4167586	Eli Lilly	Phase 1	36
AZD9550 + AZD6234 + Placebo comparator	AstraZeneca	Phase 2	39